Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan.

Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM.

Ann Trop Med Parasitol. 2010 Jun;104(4):319-26. doi: 10.1179/136485910X12743554760144.

PMID:
20659392
2.

Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria.

Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D.

Cochrane Database Syst Rev. 2014 Jan 20;1:CD010927. doi: 10.1002/14651858.CD010927. Review.

3.

Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.

Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, Diatta M, Ama MV, Tine R, Ndiaye JL, Evi JB, Same-Ekobo A, Faye O, Koné M.

Malar J. 2011 Jul 20;10:198. doi: 10.1186/1475-2875-10-198.

4.

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children.

Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G.

Clin Infect Dis. 2009 Dec 1;49(11):1629-37. doi: 10.1086/647946.

6.

Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN.

Lancet. 2007 Mar 3;369(9563):757-65.

7.

Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan.

Elamin SB, Awad AI, Eltayeb IB, Elmardi KA, Hassan AH, Mohamed AO, Malik EM, Mohamad TA.

Eur J Clin Pharmacol. 2010 Mar;66(3):231-7.

PMID:
20187287
8.

Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.

Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, Ouédraogo JB.

Clin Infect Dis. 2007 Dec 1;45(11):1453-61. Epub 2007 Oct 22.

9.

Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children.

Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, Ndikum VN, Evehe MS, Froeschl G, Heumann C, Mansmann U, Ogundahunsi O, Mbacham WF.

Malar J. 2015 Jan 28;14:27. doi: 10.1186/s12936-014-0521-2.

10.

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.

Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H.

PLoS One. 2008 Jun 11;3(6):e2390. doi: 10.1371/journal.pone.0002390.

11.

Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.

Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U.

Malar J. 2011 Feb 28;10:50. doi: 10.1186/1475-2875-10-50.

12.

Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.

Onyamboko MA, Fanello CI, Wongsaen K, Tarning J, Cheah PY, Tshefu KA, Dondorp AM, Nosten F, White NJ, Day NP.

Antimicrob Agents Chemother. 2014 Sep;58(9):5528-36. doi: 10.1128/AAC.02682-14. Epub 2014 Jul 7.

13.

Artemisinin-based combination therapy for treating uncomplicated malaria.

Sinclair D, Zani B, Donegan S, Olliaro P, Garner P.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007483. doi: 10.1002/14651858.CD007483.pub2. Review.

PMID:
19588433
14.

Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria.

Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, Rosenthal PJ, Kamya MR, Tappero JW, Dorsey G.

Clin Infect Dis. 2014 Aug 15;59(4):509-16. doi: 10.1093/cid/ciu353. Epub 2014 May 13.

15.

A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya.

Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, Kariuki S, Kachur SP, Slutsker L, Desai M.

Malar J. 2013 Jul 19;12:254. doi: 10.1186/1475-2875-12-254.

16.

[Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China].

Wang SQ, Christophel E, Lin SG, Meng F, Hu XM, Wang GZ, Liu J, Zeng LH.

Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2008 Feb 28;26(1):50-2. Chinese.

PMID:
18637586
18.

A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.

Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, Singhasivanon P, Jelinek T, White NJ, Nosten FH.

Malar J. 2005 Sep 22;4:46.

19.

Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.

Ibrahium AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, Malik EM, Adam I.

Ann Trop Med Parasitol. 2007 Jan;101(1):15-21.

PMID:
17244406
20.

Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria.

Keating GM.

Drugs. 2012 May 7;72(7):937-61. doi: 10.2165/11203910-000000000-00000. Review.

PMID:
22515619
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk